These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 26309071)
61. Burden of prescription drug costs in the United States. Curtiss FR J Manag Care Pharm; 2003; 9(1):91-2. PubMed ID: 14613372 [No Abstract] [Full Text] [Related]
62. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle. Garrison LP Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218 [No Abstract] [Full Text] [Related]
64. European perspective on the costs and cost-effectiveness of cancer therapies. Drummond MF; Mason AR J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939 [TBL] [Abstract][Full Text] [Related]
65. Managing oncology drug costs in a constrained environment. Clark P Clin Adv Hematol Oncol; 2019 Feb; 17(2):90-93. PubMed ID: 30845110 [No Abstract] [Full Text] [Related]
67. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. Henry D; Taylor C Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632 [TBL] [Abstract][Full Text] [Related]
68. Reimbursement for chemotherapy drugs used in office practice. Bailes JS Oncology (Williston Park); 1991 Oct; 5(10):27. PubMed ID: 1838268 [No Abstract] [Full Text] [Related]
69. Another war on drugs. European countries turn to 'reference pricing' in battle against soaring cost of pharmaceuticals. Hensley S Mod Healthc; 1999 Nov; 29(46):38-9. PubMed ID: 10662043 [No Abstract] [Full Text] [Related]
70. Critical issue is rapidity of review of new drugs. Rodger A BMJ; 2008 Jul; 337(7662):a779. PubMed ID: 18625599 [No Abstract] [Full Text] [Related]
71. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. Augurzky B; Göhlmann S; Gress S; Wasem J Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725 [TBL] [Abstract][Full Text] [Related]
72. Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals. Blumenthal DM; Goldman DP; Jena AB Ann Intern Med; 2017 Feb; 166(3):219-220. PubMed ID: 27951598 [No Abstract] [Full Text] [Related]
73. Indication-specific pricing for cancer drugs. Bach PB JAMA; 2014 Oct 22-29; 312(16):1629-30. PubMed ID: 25279433 [No Abstract] [Full Text] [Related]
74. Economic and quality of life outcomes: the four-step pharmacoeconomic research model. Arikian SR; Suver J; Einarson T; Doyle J Oncology (Williston Park); 1995 Nov; 9(11 Suppl):33-6. PubMed ID: 8608054 [TBL] [Abstract][Full Text] [Related]
75. Soaring price of cancer drugs leads plans to new approaches. Sipkoff M Manag Care; 2007 Aug; 16(8):12-3. PubMed ID: 17886533 [No Abstract] [Full Text] [Related]
76. A different kind of hope. Henry R Br J Nurs; 2017 May; 26(10):S3. PubMed ID: 28541110 [No Abstract] [Full Text] [Related]